Pages that link to "Q33957962"

The following pages link to Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? (Q33957962):

Displayed 13 items.

• A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors (Q33431483) ‎ (← links)
• Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. (Q33433311) ‎ (← links)
• Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. (Q37520379) ‎ (← links)
• Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis (Q37611674) ‎ (← links)
• The role of endoglin in kidney fibrosis (Q38273688) ‎ (← links)
• Bone Morphogenetic Proteins in Vascular Homeostasis and Disease (Q38872877) ‎ (← links)
• DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1. (Q40427193) ‎ (← links)
• The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells (Q40996773) ‎ (← links)
• A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. (Q50858313) ‎ (← links)
• Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer. (Q64929569) ‎ (← links)
• Emerging Systemic Therapies for Colorectal Cancer (Q88549071) ‎ (← links)
• Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition (Q91760986) ‎ (← links)
• A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma (Q92875017) ‎ (← links)